By in

Share Option Scheme

Press Release                                                                                                                                        25 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or the “Company” or the “Group”)

Share Option scheme

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that the Company has adopted the Sativa Investments PLC Share Plan (the “Scheme”), to recognise the work accomplished by the Sativa team to date, to incentivise it going forward, and to enable the Group to continue to attract high calibre recruits as the business expands. 

The Scheme incorporates a tax-advantaged enterprise management incentive (“EMI”) scheme for the grant of share options to key employees, and also allows for the grant of non-tax-advantaged (“NTA”) share options to certain employees, contractors and third parties.  

Initial grants under the Scheme have been made over a total of 24,072,225 ordinary shares of 0.25p each in the Company (“Ordinary Shares”), representing approximately 4.7 per cent of the Company’s current issued share capital.

Of the Ordinary Shares the subject of the options, 13,555,558 (78 per cent) have been made available by Geremy Thomas, the founder and Chief Executive Officer of Sativa, surrendering personal options, otherwise exercisable at a price of 0.5p per share, which had been granted to him on the Company’s admission to trading on the NEX Exchange Growth Market. 

The following options are being granted under the scheme to Directors and Persons Discharging Managerial Responsibilities (“PDMRs”). 

Joseph Colliver, Chief Financial Officer, has been granted options over 3,350,000 Ordinary Shares at an exercise price of 1.5p per share, with one third vesting on the first anniversary of the date of grant, one third on the second anniversary, and one third on the third anniversary.  Joseph has been granted options over a further 4,444,447 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the third anniversary of the date of grant, if remaining in employment of the Company. 

Angus Kerr, a non-Executive Director, has been granted options over 2,222,222 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the third anniversary of the date of grant, if remaining in position. 

Sir Alasdair Breckenridge, a member of the Company’s Medicinal Cannabis Advisory Board, has been granted options over 500,000 Ordinary Shares at an exercise price of 2.25p per share, exercisable on the fifth anniversary of the date of grant, if remaining in position.  

Four non-PDMR employees have been granted options over a further 6,888,889 Ordinary Shares at an exercise price of 2.25p per share, with one third exercisable on the first anniversary of the date of grant, one third on the second anniversary, and one third on the third anniversary, if remaining in employment of the Company. 

Jonathan Wearing, Chairman of Sativa Investments, said: “The implementation of a share option scheme is an important part of the development of the business and has been considered carefully by the Remuneration Committee.  It is indicative of the likely potential of Sativa that Geremy Thomas, the Chief Executive Officer, has committed a proportion of the share options awarded to him personally at listing.” 

In addition, Geremy Thomas has surrendered options over a further 6,666,667 Ordinary Shares granted to him on the Company’s admission to trading on the NEX Exchange Growth Market, also with an exercise price of 0.5p per share.  These options have now been granted as NTA options to JH Racing A&P LTD to fund sponsorship of the Sativa car in the Ginetta Junior Championship 2019 / 2020 season.  The racing series is broadcast on ITV 4 and reaches a combined audience of 19.4 million viewers and a trackside audience of 385,000.  The car and team are heavily branded Sativa Investments PLC and were sponsored previously in Sativa’s name at Geremy Thomas’ personal expense.  

Following the grant of the options as set out above, options over a total of 154,072,225 Ordinary Shares, representing 30 per cent of the Company’s current issued share capital, will be outstanding.

On 18 July 2018, Geremy Thomas exercised options over 500,000 Ordinary Shares and sold these shares at a price of 5p per share. Details of these transactions were inadvertently not announced at the time.

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4633 / 4634


+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Geremy Thomas

2

Reason for the notification

a)

Position/status

Director / CEO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Surrender of share options

c)

Price(s) and volume(s)

 

20,222,225 ordinary shares at an exercise price of 0.5p (£0.005)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Joseph Colliver

2

Reason for the notification

a)

Position/status

Director / CFO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

3,350,000 at an exercised at 1.5p (£0.015), equal to £50,250

4,444,447 at an exercise price of 2.25p (£0.0225), equal to £100,000

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Angus Kerr

2

Reason for the notification

a)

Position/status

Non-Executive Director / Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 

2,222,222 ordinary shares at an exercise price of 2.25p (£0.0225)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sir Alasdair Breckenridge

2

Reason for the notification

a)

Position/status

Member of the Medical Advisory Board / Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

 

500,000 ordinary shares at an exercise price of 2.25p (£0.0225)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

24th October 2018

f)

Place of the transaction

NEX Exchange Growth Market

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Geremy Thomas

2

Reason for the notification

a)

Position/status

Director / CEO Sativa Investments PLC

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

 Sativa Investments PLC

b)

LEI

213800UBHKVCNXTZEZ74

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.25p each

 

ISIN: GB00BFX17474

b)

Nature of the transaction

Exercise of share options and sale of shares

c)

Price(s) and volume(s)

 

500,000 ordinary shares acquired at an exercise price of 0.5p per share (£0.005) and  sold at 5p per share (£0.05)

d)

Aggregated information

– Aggregated volume

– Price

 

e)

Date of the transaction

18th July 2018

f)

Place of the transaction

NEX Exchange Growth Market

 

By in

Option agreement on 298,806 sq ft glasshouse signed

Press Release                                                                                                                                                    24 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Option agreement on 298,806 sq ft glasshouse signed

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has now signed the option agreement to lease a 7.53 acre site for medicinal cannabis production in Wiltshire on which the Company intends to build a glasshouse facility.  Further details are included in the Company’s announcement of Thursday 18 October 2018. 

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Change in Board responsibilities

Press Release                                                                                                                                                      24 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. 

Sativa Investments PLC

 (“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Change in Board responsibilities

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, announces that Mark Blower, currently an Executive Director of the Company, is moving to a non-Executive Director role with immediate effect.

–  Ends  –

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com

By in

Heads of Terms for an option to lease a 7.53 acre UK site for medicinal cannabis production

Press Release                                                                                                                                                    18 October 2018

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

Sativa Investments PLC

(“Sativa” or “Sativa Investments” or “the Company” or “the Group”)

Heads of Terms for an option to lease a 7.53 acre UK site for medicinal cannabis production

Sativa Investments PLC (NEX: SATI), the UK’s first medicinal cannabis investment vehicle, has signed Heads of Terms for an £85K option to lease a 7.53 acre development site in Wiltshire.  

The Board expects the option agreement to be signed later today, Thursday, 18 October 2018.  On exercise of the option agreement, the Company intends to construct a glasshouse of up to 6.86 acres (298,806 sq ft) on the site, as its moves to becoming a seed to consumer medicinal cannabis business with a UK focus.  The site will be used to grow cannabis plants for the production of medicinal cannabis and cannabidiol (“CBD”) products, which by law must contain a maximum of 0.2 per cent tetrahydrocannabinol (“THC”).  The site will also host an extraction facility and offices. 

The Directors believe that the glasshouse’s location would be unique, in so far as it would sit beside an existing 3.6MW capacity bio-digester plant from which it will be entitled to take the plant’s surplus heat, purchasing electricity at significantly below market rates, making it the first green-powered medicinal cannabis canopy in the UK.  The Directors believe that this in turn will enable Sativa to offer products to the market at highly competitive rates.  The Company intends to be a leader in the quality of UK grown product. 

Sativa subsidiary George Botanicals already has a UK Home Office hemp growers’ licence, involving a low THC crop, and has applied to the UK Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing licence.  The glasshouse already has planning permission for its build and the site will comply with all Home Office conditions for the Permitted Use of the product including state of the art security. 

On exercise, Sativa will enter into a 25-year term lease and begin development of the site.  Once entered into, the option may be exercised at any time up to 1 July 2019 and can be extended for a further three months subject to payment of a further £15K. 

Global industry standards suggest that each square foot of canopy produces 40 grams of raw cannabis plant which, in the last 12 months, has had an average wholesale gross revenue of £4.00 per gram.  The Directors intend that 65 per cent of the glasshouse, an estimated 194,224 sq ft of the total 298,806 sq ft, will be harvested, with the remaining third being used for ancillary space such as walkways and seedlings.  The build-out costs for a high-tech facility are estimated to be £35 per sq ft.

The build spend for the 7.53 acre site, including the 298,806 sq ft glasshouse plus an extraction facility and offices, is estimated to be £10.5 million, for which the Company intends to raise funds via an equity Placing or Offer, or its own cash resources at the appropriate time.  

Sativa will be advised on cannabis strain selection by Veritas Pharma Inc. (“Veritas”), the Canadian-based emerging pharmaceutical company, through Veritas’ subsidiary company Cannevert Therapeutics Ltd.  Sativa invested £117K in Veritas in May 2018.   

As part of the consideration for the option, Sativa will also offer the proprietors of the farm on which the glasshouse will be built, an option to acquire 2 million ordinary shares in the Company at a price of 5 pence per share, once the development is completed and operational. 

Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “Sativa is the first UK medicinal cannabis vehicle and continues its first-mover advantage with this major step towards being the UK’s first seed to consumer business.  

“The Company already has a cannabis-testing laboratory and a CBD wholesale and retail business in George Botanicals.”  

The Directors of the Company accept responsibility for the contents of this announcement.

–  Ends  –

 

For further information please contact:

 

Geremy Thomas
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller and Lucy Williams
Peterhouse Capital Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Abchurch Communications
Julian Bosdet
Dylan Mark
Alejandra Campuzano
Switchboard
SativaInvestments@abchurch-group.com

Joseph Colliver
Chief Financial Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

+44 (0) 20 7469 4631
+44 (0) 20 7469 4633
+44 (0) 20 7469 4634
+44 (0) 20 7469 4630
www.abchurch-group.com

Notes to Editors

Sativa looks for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector. The Company’s pan-European, end-to-end, seed to consumer investment strategy focuses on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily permitted.  Sativa has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in an investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa acquires can either be public or private.

Sativa Investments has four investments to date including Canadian-based and dual-listed emerging global pharmaceutical company, Veritas Pharma Inc., Toronto-based Pharma-Tech company Rapid Dose Therapeutics Inc., which owns the patent-pending proprietary QuickStrip™ technology, UK-based CBD products provider George Botanicals, and PhytoVista Laboratories, a UK testing laboratory meeting the need for regulatory and batch testing of products such as CBD oil.

The Company has a presence in Germany through its joint venture with Germany’s Lexamed GmbH; Sativa Germany GmbH, of which it has a 60 per cent majority stake in for the production of medicinal cannabis and CBD products.

Sativa is also focussed on researching and developing medicinal cannabis products by funding university research grants of medicinal cannabis through its Sativa Foundation.

The Company’s Board and Medicinal Cannabis Advisory Board have a combined 60 years’ industry experience, with significant pharmaceutical strength and experience and extensive contacts in the industry, which includes pharmacologist Sir Alasdair Breckenridge, who liaises with the Home Office and the Medicines and Healthcare products Regulatory Agency (“MHRA”), which he has chaired, for the legalisation of medicinal cannabis in the UK  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: www.sativainvestments.com